# Ocular Therapeutix CEO Pravin Dugel Confirms Q4 FDA Filing for AXPAXLI After SOL-1 Win

> Ocular Therapeutix plans to file an NDA for AXPAXLI in Q4 after SOL-1 showed superiority to EYLEA, with more than two-thirds of patients needing no rescue treatment.

- Published: 2026-11-22T20:23:22+00:00
- Section: Research & Clinical Trials
- Author: News Desk
- URL: https://newsforagent.com/news/2026-11-22/ocular-therapeutix-q4-fda-filing-axpaxli
- Source: [Yahoo](https://finance.yahoo.com/healthcare/articles/ocular-therapeutix-targets-q4-fda-191211364.html?ref=biztoc.com)

## Key takeaways

- Ocular Therapeutix remains on track to submit a U.S. marketing application for AXPAXLI in the fourth quarter.
- In the Phase 3 SOL-1 trial, AXPAXLI showed superiority to EYLEA with a p-value below 0.0006.
- More than two-thirds of SOL-1 patients did not require rescue treatment one year after a single AXPAXLI injection.
- Ocular moved SOL-R's primary endpoint to week 40 from week 56 and extended planned unmasking to week 96.

Ocular Therapeutix remains on track to file a new drug application for AXPAXLI in the fourth quarter, CEO Pravin Dugel said at the UBS Global Biopharma Conference in London, according to [Yahoo](https://finance.yahoo.com/healthcare/articles/ocular-therapeutix-targets-q4-fda-191211364.html?ref=biztoc.com). The filing relies on the Phase 3 SOL-1 trial, in which AXPAXLI showed superiority to EYLEA with a p-value below 0.0006.

## Dugel Details AXPAXLI Filing Plans

[Ocular Therapeutix](https://akta.pro/company-profiles/0000mby/ocular-therapeutix) is a Bedford, Massachusetts-based biopharmaceutical company that develops ophthalmic therapeutics on its ELUTYX bioresorbable hydrogel platform, commercializing DEXTENZA and advancing AXPAXLI through Phase 3 trials for wet age-related macular degeneration and diabetic retinopathy. AXPAXLI is a tyrosine kinase inhibitor the company is developing as a maintenance treatment for wet AMD.

Dugel said more than two-thirds of SOL-1 patients did not require rescue treatment one year after a single AXPAXLI injection. He said the company believes the drug could provide sustained disease control after patients receive initial anti-VEGF injections.

Ocular held a Type C meeting with the U.S. Food and Drug Administration in May and a pre-application meeting in the third quarter, Dugel said. He said the FDA's standards for a single-trial submission include a well-masked, properly powered study, a p-value below 0.001 and safety data from at least 300 patients exposed to the drug. Ocular has a special protocol assessment with the FDA for SOL-1.

Dugel did not provide a projected approval or launch date. He said the FDA typically responds about 60 days after a submission on whether it will accept an application for review, and that Ocular expects an efficient review under its 505(b)(2) filing pathway.

## SOL-R and SOL-X Study Changes

Ocular moved SOL-R's primary endpoint to week 40 from week 56 and extended its planned unmasking to week 96. Dugel said delaying the unmasking reduces the risk of a major amendment during the anticipated U.S. review cycle and allows the company to study superiority against high-dose EYLEA. Ocular expects to use safety data from approximately 130 SOL-R patients in its submission package.

The company also extended treatment intervals in its open-label SOL-X extension study to 48 weeks from 24 weeks. Dugel said the SOL-1 results gave Ocular confidence to examine annual dosing rather than duplicate six-month data expected from SOL-R.

## Funding and Trial History

According to akta.pro [company records](https://akta.pro/company-data), Ocular reported positive SOL-1 Phase 3 topline data in February 2026 showing 74.1% of AXPAXLI subjects maintained vision at Week 36 versus 55.8% for aflibercept, with a p-value of 0.0006. The same records show the company randomized the first patient in its HELIOS-3 Phase 3 registrational trial of AXPAXLI in non-proliferative diabetic retinopathy in November 2025.

Ocular's funding history includes a $475 million September 2025 underwritten offering of 37,909,018 shares at $12.53 per share, a $325 million February 2024 private placement and a $115.1 million December 2023 public offering of 35,420,000 shares, according to the same records.

## Earlier AXPAXLI Milestones

In October 2026, Ocular said it planned a Q4 FDA filing for AXPAXLI after SOL-1 showed superiority over an approved anti-VEGF therapy and had formalized a single-trial approval pathway, MarketBeat reported. In September 2026, Ocular reported Q2 2026 results confirming the Q4 2026 NDA filing for wet AMD, with R&D spending of $54.1 million and a net loss of $78.8 million, according to Insider Trading & Hedge Fund Data.

## What to Watch Next

Ocular expects to provide guidance on diabetic retinal disease in 2027, Dugel said. The company expects the SOL-R trial readout in the first quarter of 2028, according to Insider Trading & Hedge Fund Data.

## Companies in this story

- [Ocular Therapeutix company profile](https://akta.pro/company-profiles/0000mby/ocular-therapeutix) · website: http://www.ocutx.com

---
News for Agent · https://newsforagent.com/llms.txt
